Hydrochlorothiazide/Olmesartan Medoxomil Aurobindo (Olmesartan Medoxomil, Hydrochlorothiazide)

Hydrochlorothiazide/Olmesartan Medoxomil Aurobindo is indicated for the management of high blood pressure in patients who need more than one antihypertensive agent.

• Monotherapy-resistant hypertension where additional blood pressure reduction is required.
• Patients who benefit from combined angiotensin II receptor blockade and thiazide diuretic effects.
• Situations where a single-pill regimen can improve adherence to treatment.
• Cases where clinicians aim to target both vascular tone and plasma volume simultaneously.
• Patients with comorbid conditions such as mild chronic kidney disease who require careful volume management.
• Individuals who prefer a fixed-dose combination to reduce the number of daily tablets.

• Olmesartan medoxomil is an angiotensin II receptor blocker that selectively inhibits the AT1 receptor, preventing angiotensin II–mediated vasoconstriction and aldosterone release. Hydrochlorothiazide acts on the distal convoluted tubule of the nephron, blocking NaCl reabsorption, which increases urinary sodium and water excretion, lowers plasma volume, and contributes to a reduction in peripheral resistance. The combined actions produce additive blood‑pressure lowering effects.

Like other antihypertensive combinations, Hydrochlorothiazide/Olmesartan Medoxomil Aurobindo may cause a range of adverse reactions, most of which are mild and reversible.

Common

• Dizziness or light‑headedness, especially after the first doses.
• Increased urination or a feeling of thirst.
• Mild electrolyte disturbances such as low potassium or sodium.
• Headache or fatigue.
• Gastrointestinal discomfort such as nausea or mild abdominal pain.
• Transient increase in blood glucose levels.

Serious

• Severe hypotension or syncope.
• Acute kidney injury or significant rise in serum creatinine.
• Hyperkalemia or marked electrolyte imbalance.
• Angioedema or severe allergic skin reactions.
• Liver function abnormalities or hepatitis.
• Severe skin reactions such as Stevens‑Johnson syndrome.

When prescribing Hydrochlorothiazide/Olmesartan Medoxomil Aurobindo, clinicians should consider several precautionary factors to ensure safe use.

• Assess renal function before initiation and monitor periodically, as both components are excreted via the kidneys.
• Evaluate electrolyte status, particularly potassium and sodium levels, due to the diuretic effect.
• Use caution in patients with a history of angioedema or hypersensitivity to ARBs.
• Avoid in individuals with severe hepatic impairment, which may affect drug metabolism.
• Consider the risk of hypotension in patients already receiving other antihypertensives.
• Monitor blood glucose in diabetic patients, as thiazides can affect glycemic control.
• Counsel patients about standing up slowly to reduce orthostatic dizziness.

Hydrochlorothiazide/Olmesartan Medoxomil Aurobindo can interact with other medicines, influencing blood pressure control or electrolyte balance.

Avoid

• Concomitant use with other potent ARBs or ACE inhibitors, which may increase risk of hyperkalemia and renal dysfunction.
• Combined therapy with lithium, as thiazides can raise lithium concentrations and precipitate toxicity.
• NSAIDs taken regularly, because they may blunt the antihypertensive effect and worsen renal function.

Use with caution

• Diuretics other than thiazides, which can exacerbate electrolyte disturbances.
• Potassium‑sparing agents or supplements, due to additive risk of hyperkalemia.
• Antidiabetic drugs, since thiazides may impair glucose tolerance.
• Antihypertensive agents such as beta‑blockers or calcium channel blockers, requiring dose adjustments.